Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 8, pp. 710-721
Open Access | Times Cited: 151

Showing 51-75 of 151 citing articles:

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy
Laura D'Alessio‐Sands, Joshua Gaynier, Victoria Michel‐Milian, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
KRAS Oncoprotein Signaling in Cancer
Piro Lito
New England Journal of Medicine (2025) Vol. 392, Iss. 3, pp. 296-298
Closed Access
Advancements in gene therapies targeting mutant KRAS in cancers
Yuhang Wang, Thuỳ Anh Bùi, Xinpu Yang, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Thérapies moléculaires ciblées en cancérologie pulmonaire
Alice Mogenet, Laurent Greillier, Pascale Tomasini
Encyclopédie médico-chirurgicale. Pneumologie (2025) Vol. 36, Iss. 1, pp. 1-9
Closed Access
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Identification of Structurally Novel KRASG12C Inhibitors through Covalent DNA-Encoded Library Screening
David Huang, Francesco Manoni, Zhen Sun, et al.
Journal of Medicinal Chemistry (2025)
Open Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Exome‐wide molecular insights from blood and urine liquid biopsies in genitourinary cancers
Eric Jia, Tiantian Zheng, Yong Huang, et al.
UroPrecision (2025)
Open Access
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen
Alexander Kretzschmar
Onkologische Welt (2025) Vol. 16, Iss. 01, pp. 6-7
Closed Access
The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results
Stefan Kasper, Martin Sebastian
Deutsches Ärzteblatt international (2025)
Closed Access
Lung Cancer: Targeted Therapy in 2025
Nicole Bouchard, Nathalie Daaboul
Current Oncology (2025) Vol. 32, Iss. 3, pp. 146-146
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective
Vimal H. Prajapati, Ankit Kumar Singh, Adarsh Kumar, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Second-line therapy for KRAS-positive metastatic non-small cell lung cancer
Martin Svatoň
Onkologie (2025) Vol. 19, Iss. 1, pp. 29-32
Closed Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Targeting RAS and associated proteins
Matthias Müller, Roger S. Goody, Daniel Rauh
Elsevier eBooks (2025)
Closed Access
Immunotherapy in advanced, KRAS G12C-mutant non-small-cell lung cancer: current strategies and future directions
Nadia Ghazali, Marina Chiara Garassino, Natasha B. Leighl, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Pancreatic cancer: failures and hopes—a review of new promising treatment approaches
Vittore Cereda, Mario D’Andrea
Exploration of Targeted Anti-tumor Therapy (2025) Vol. 6
Open Access
Diagnostik und Therapiekonzepte für das Pankreaskarzinom – Update 2024
Angelika Kestler, Thomas Seufferlein
Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 25-41
Closed Access
Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials
Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Recent advances in therapeutic strategies for non-small cell lung cancer
Po‐Lan Su, Naoki Furuya, Atif Asrar, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access

Scroll to top